Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro

Leiping Zeng(Wuhan Institute of Virology), Lei S. Qi(Nantong University), Sarah A. Stanley(University of California, Berkeley), Anastasia P. Kadina(Synthego (United States)), Annelise E. Barron(Stanford University), Jordan Spatz(Stanford University), Augustine Chemparathy(Stanford University), Adrianna E. Zepeda(Synthego (United States)), John Walker(Synthego (United States)), Kevin Holden(Synthego (United States)), Xammy Nguyenla(Oregon Health & Science University), Jennifer R. Cochran(Stanford University), Draven A. Rane(Stanford University), Timothy R. Abbott(Stanford University), Benjamin A. Pinsky(Stanford University), Xueqiu Lin(Stanford University), Nigel Temperton(Medway School of Pharmacy), Marie La Russa(Stanford University), Catherine A. Blish(Chan Zuckerberg Initiative (United States)), Arjun Rustagi(Stanford University), Michael D. Connolly(Lawrence Berkeley National Laboratory), Haifeng Wang(Stanford University), Xinyi Chen(Stanford University), Yanxia Liu(Stanford University), Mengting Han(Beijing University of Chemical Technology), Yan‐Yu Zhu(Stanford University), David B. Lewis(Stanford Medicine), Saket Jain(University of California, San Francisco)
Nature Communications
May 19, 2022
Cited by 51


Related Papers